ArticleDiscover oncology2025
p53/PD-L1 co-expression predicts poor prognosis in diffuse large B-cell lymphoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical characteristics and survival of p53 and Programmed death-ligand 1 (PD-L1) co-expression in diffuse large B-cell lymphoma (DLBCL) patients.
methodsImmunohistochemistry (IHC) was used to detect the expression of p53 and PD-L1 in tumor cells of 176 patients with DLBCL. Clinical data were retrospectively examined along with long-term follow-up. Correlation between the expression of p53 and PD-L1 and the clinicopathological characteristics of the patients was assessed. Impact of Rituximab (R) on prognosis among DLBCL patients with positive expression of p53 and PD-L1 was evaluated.
resultsp53 expression, PD-L1 expression, and p53/PD-L1 co-expression were present in 44.9%, 42.0%, and 25.6% of patients with DLBCL, respectively. No significant differences existed in the clinicopathological characteristics between patients with positive and negative p53 expression and between patients with positive and negative PD-L1 expression. However, more co-expression of p53/PD-L1 was observed in patients with non-germinal center B-cell-like (non-GCB) subtypes (p = 0.005). There was a significant positive correlation between p53 and PD-L1 expression (r = 0.273, p < 0.001). Survival analysis indicated that patients exhibiting p53/PD-L1 co-expression had decreased progression-free survival (PFS) and overall survival (OS ) compared to those demonstrating positive expression of either p53 or PD-L1, and in addition, both negative p53/PD-L1 expression. Rituximab failed to substantially modify the prognosis of patients. p53/PD-L1 co-expression is an independent indicator of adverse prognosis.
conclusionsCo-expression of p53/PD-L1 in DLBCL patients implies an unfavorable prognostic group, which doesn't derive benefit from Rituximab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.